Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neonatal developmental and epileptic encephalopathy with movement disorder and arthrogryposis: A shared phenotype across brain-expressed sodium channelopathies.

Epilepsia·2026
Same author

Caregiver-Reported Epilepsy Management in Juvenile-Onset Huntington Disease.

Pediatric neurology·2026
Same author

Ripples in Time and Space Regulate Epileptic Firing in the Hippocampus.

Epilepsy currents·2026
Same author

Febrile Seizures: Clinical Insights From Decades of the National Institutes of Neurological Diseases and Stroke (NINDS) Support.

Epilepsy currents·2026
Same author

Diagnostic accuracy of echocardiography in identifying heart failure related pleural effusions.

Respiratory medicine·2026
Same author

Infantile epileptic spasms syndrome: Mechanisms and therapeutic approaches.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2025
Same journal

R&D productivity trends for biopharma companies in Asia and emerging markets.

Nature reviews. Drug discovery·2026
Same journal

Growth in clinical research capability in China and impact on the pharmaceutical sector.

Nature reviews. Drug discovery·2026
Same journal

Circular RNA guides exon skipping in DMD.

Nature reviews. Drug discovery·2026
Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026
Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026
Same journal

Designing GPCR-targeted miniproteins.

Nature reviews. Drug discovery·2026
See all related articles

Related Experiment Video

Updated: May 29, 2026

Generation of Local CA1 γ Oscillations by Tetanic Stimulation
08:02

Generation of Local CA1 γ Oscillations by Tetanic Stimulation

Published on: August 14, 2015

Ezogabine (retigabine).

Carl E Stafstrom1, Seden Grippon, Peter Kirkpatrick

  • 1University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53705, USA. stafstrom@neurology.wisc.edu

Nature Reviews. Drug Discovery
|October 1, 2011
PubMed
Summary
This summary is machine-generated.

Ezogabine, also known as retigabine, is a potassium channel opener approved for adjunctive treatment of partial-onset seizures in adults. It received FDA approval in June 2011 and EU marketing authorization in March 2011.

More Related Videos

Nitroreductase/Metronidazole-Mediated Ablation and a MATLAB Platform (RpEGEN) for Studying Regeneration of the Zebrafish Retinal Pigment Epithelium
13:12

Nitroreductase/Metronidazole-Mediated Ablation and a MATLAB Platform (RpEGEN) for Studying Regeneration of the Zebrafish Retinal Pigment Epithelium

Published on: March 2, 2022

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Related Experiment Videos

Last Updated: May 29, 2026

Generation of Local CA1 γ Oscillations by Tetanic Stimulation
08:02

Generation of Local CA1 γ Oscillations by Tetanic Stimulation

Published on: August 14, 2015

Nitroreductase/Metronidazole-Mediated Ablation and a MATLAB Platform (RpEGEN) for Studying Regeneration of the Zebrafish Retinal Pigment Epithelium
13:12

Nitroreductase/Metronidazole-Mediated Ablation and a MATLAB Platform (RpEGEN) for Studying Regeneration of the Zebrafish Retinal Pigment Epithelium

Published on: March 2, 2022

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Partial-onset seizures are a common form of epilepsy.
  • Current treatments have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To summarize the approval status and indications of ezogabine (retigabine).

Main Methods:

  • Review of regulatory approval documents and drug information.

Main Results:

  • Ezogabine (Potiga) received U.S. Food and Drug Administration (FDA) approval in June 2011.
  • Retigabine (Trobalt) received European Union marketing authorization in March 2011.

Conclusions:

  • Ezogabine/retigabine is approved as an adjunctive therapy for partial-onset seizures in adult patients.
  • The drug represents a new treatment option for epilepsy management.